Isaltis SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Isaltis SAS - overview
Established
2011
Location
Lyon, -, France
Primary Industry
Chemicals
About
Isaltis SAS is a biopharmaceutical company focused on developing innovative therapeutic solutions to address unmet medical needs, particularly in metabolic disorders and rare diseases. Their expertise lies in advancing patient outcomes through effective biopharmaceuticals. Founded in 2011, Isaltis SAS is based in Lyon, France, specializing in the creation of therapeutic solutions. The company was acquired by Macco Organiques Inc.
in April 2018, expanding its operations into North America and Europe. CEO Jean-Michel Alarcon leads the company, which has engaged in two deals to date. Isaltis specializes in developing and commercializing therapeutic solutions aimed at unmet medical needs. Their biopharmaceuticals target various conditions, focusing on improving patient outcomes in clinical settings.
Isaltis' clientele includes hospitals and healthcare providers across Europe and North America, ensuring that their products are accessible to healthcare professionals and patients alike, supported by thorough scientific research and clinical data. In the most recent year, Isaltis SAS reported revenue of USD 1. 66 bn with an EBITDA of USD -133,373. 8 for 2022.
The company's revenue model is B2B, relying on partnerships with healthcare institutions and pharmaceutical distributors, with direct sales strategies to hospitals and clinics. Following its acquisition, Isaltis SAS aims to leverage its resources to launch new therapeutic products designed for the North American and European markets. The company plans to expand its geographic reach and enhance its product lineup utilizing recent funding to enhance distribution channels and establish partnerships across targeted regions. The acquisition will facilitate greater access to their innovative solutions, aligning with their growth strategy.
Current Investors
Credit Mutuel Equity, Dealbydeal Invest
Primary Industry
Chemicals
Sub Industries
Specialty Pharmaceuticals, Chemicals
Website
www.isaltis.com
Total Amount Raised
Subscriber access only
Isaltis SAS - timeline of key events
Isaltis SAS - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Jan 31, 2019 | Jan 31, 2020 | Jan 31, 2021 | Jan 31, 2022 | Jan 31, 2023 | Jan 31, 2024 | Jan 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,118,253 | 1,357,287 | - | 1,415,943 | 1,559,514 | 1,314,287 | 1,397,723 | - | - | - |
| % Revenue Growth (YoY) | - | 21.4% | - | - | - | (15.7%) | 6.3% | - | - | - |
| EBITDA (USD) | (586,593) | (519,009) | - | (382,389) | 24,701 | 23,033 | (113,431) | - | - | - |
| Operating Income (USD) | (606,828) | (528,045) | - | (397,344) | 4,144 | (114) | (136,888) | - | - | - |
| Operating Margin | (54.3%) | (38.9%) | - | (28.1%) | 0.3% | (0.0%) | (9.8%) | - | - | - |
| % EBITDA Margin | (52.5%) | (38.2%) | - | (27.0%) | 1.6% | 1.8% | (8.1%) | - | - | - |
| NET Income (USD) | (723,265) | (2,416,575) | - | (2,980,603) | (507,982) | (498,443) | (613,942) | - | - | - |
| % Net Margin | (64.7%) | (178.0%) | - | (210.5%) | (32.6%) | (37.9%) | (43.9%) | - | - | - |
Isaltis SAS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Isaltis SAS | - | ||||||||
| Company Formation | Completed | Isaltis SAS | - |
Displaying 1 - 2 of 2
Isaltis SAS - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.